Genetic and environmental origins of the co-occurrence of autistic traits, anxiety and depression: Evidence from meta-analysis and twin study.

J Affect DisordJul 27, 2026 (epub)
Clinical ResearchPsychiatry

Yuxuan Han, Xinying Li, Ruolei Gu et al.

✦ AI-curated · Sources linked

In 30 seconds

This study investigated the genetic and environmental origins of the co-occurrence of autistic traits, anxiety, and depression through a meta-analysis and a twin study. The meta-analysis of six twin studies revealed a genetic correlation of 0.42 and a non-shared environmental correlation of 0.15. The findings suggest overlapping influences across these traits.

Key findings

  • Genetic correlation between autistic traits and internalising symptoms was 0.42.
  • Non-shared environmental correlation was found to be 0.15.
  • The twin study indicated a common latent factor influencing the co-occurrence of traits.
  • Substantial heterogeneity was observed across estimates in the meta-analysis.

Why it matters

Understanding the shared genetic and environmental influences on autistic traits and internalising symptoms can inform screening practices. Clinicians may consider assessing for anxiety and depression in individuals with autistic traits, enhancing early intervention strategies.

Source

PubMed · PMID 42508582

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.